Reply to Carev et al: "useful supplement to the best practice of using levosimendan in cardiac surgery patients: 2.5 mg intravenous bolus for cardiopulmonary resuscitation during perioperative cardiac arrest"

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 27, Issue 6, 2013, Pages

  Toller, Wolfgang ^a   Guarracino, Fabio ^b   Landoni, Giovanni ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; LEVOSIMENDAN;

HEART ARREST; HEART MUSCLE OXYGEN CONSUMPTION; HEART SURGERY; HUMAN; LETTER; MORTALITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RESUSCITATION; RETURN OF SPONTANEOUS CIRCULATION; SURGICAL PATIENT; URINE VOLUME;

CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; HUMANS; HYDRAZONES; PYRIDAZINES;

EID: 84888252067     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2013.07.017     Document Type: Letter

References (16)

1. Carev M, Karanovic N, Kocen D, et al. Useful supplement to the best practice of using levosimendan in a heart surgery patient: 2.5 mg intravenous bolus for cardiopulmonary resuscitation during perioperative cardiac arrest. J Cardiothorac Vasc Anesth, in press, 2013
2. J.J. Krumnikl, W.G. Toller, and G. Prenner Beneficial outcome after prostaglandin-induced post-partum cardiac arrest using levosimendan and extracorporeal membrane oxygenation Acta Anaesthesiol Scand 50 2006 768 770
3. 2+ responsiveness and altered diastolic function in intact ventricular muscle Circ Res 76 1995 1036 1048
4. N.G. Perez, E. Marban, and H.E. Cingolani Preservation of myofilament calcium responsiveness underlies protection against myocardial stunning by ischemic preconditioning Cardiovasc Res 42 1999 636 643
5. V.S. Moiseyev, P. Poder, and N. Andrejevs Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
6. S.G. De Hert, S. Lorsomradee, and S. Cromheecke The effects of levosimendan in cardiac surgery patients with poor left ventricular function Anesth Analg 104 2007 766 773
7. L. Tritapepe, V. De Santis, and D. Vitale Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery Br J Anaesth 102 2009 198 204
8. ATP-channel activation but is independent of PDE-III inhibition Basic Res Cardiol 105 2010 155 167
9. Z. Papp, I. Édes, and S. Fruhwald Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan Int J Cardiol 159 2012 82 87
10. J. Puttonen, S. Kantele, and M. Kivikko Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites Clin Pharmacokinet 46 2007 235 246
11. A. Ristikankare, R. Poyhia, and H. Eriksson Effects of levosimendan on renal function in patients undergoing coronary artery surgery J Cardiothorac Vasc Anesth 26 2012 591 595
12. Z.Q. Hou, Z.X. Sun, and C.Y. Su Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction Cardiovasc Ther 31 2013 108 114
13. A. Zorlu, H. Yucel, and O.C. Yontar Effect of levosimendan in patients with severe systolic heart failure and worsening renal function Arq Bras Cardiol 98 2012 537 543
14. J.T. Parissis, S. Adamopoulos, and D. Farmakis Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart 92 2006 1768 1772
15. N.M. Parle, M.D. Thomas, and L. Dembo Repeated infusions of levosimendan: Well tolerated and improves functional capacity in decompensated heart failure - A single-centre experience Heart Lung Circ 17 2008 206 210
16. S. Antila, M. Kivikko, and L. Lehtonen Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan Br J Clin Pharmacol 57 2004 412 415